GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (MEX:BMRN) » Definitions » Capex-to-Operating-Income

Biomarin Pharmaceutical (MEX:BMRN) Capex-to-Operating-Income : 0.08 (As of Mar. 2025)


View and export this data going back to 2019. Start your Free Trial

What is Biomarin Pharmaceutical Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Biomarin Pharmaceutical's Capital Expenditure for the three months ended in Mar. 2025 was MXN-343.04 Mil. Its Operating Income for the three months ended in Mar. 2025 was MXN4,580.78 Mil.

Hence, Biomarin Pharmaceutical's Capex-to-Operating-Income for the three months ended in Mar. 2025 was 0.08.


Biomarin Pharmaceutical Capex-to-Operating-Income Historical Data

The historical data trend for Biomarin Pharmaceutical's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Capex-to-Operating-Income Chart

Biomarin Pharmaceutical Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 2.29 0.58 0.21

Biomarin Pharmaceutical Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.44 0.18 0.19 0.13 0.08

Competitive Comparison of Biomarin Pharmaceutical's Capex-to-Operating-Income

For the Biotechnology subindustry, Biomarin Pharmaceutical's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Capex-to-Operating-Income falls into.


;
;

Biomarin Pharmaceutical Capex-to-Operating-Income Calculation

Biomarin Pharmaceutical's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-2031.721) / 9889.69
=0.21

Biomarin Pharmaceutical's Capex-to-Operating-Income for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (-343.043) / 4580.775
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biomarin Pharmaceutical  (MEX:BMRN) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Biomarin Pharmaceutical Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical Business Description

Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.